Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Evaluation of the first 12 patients in a Phase I trial of rhIL-11indicated the agent was able to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury